EBITDA for ResMed (RMD)
According to ResMed's latest reported financial statements, the company's current EBITDA (TTM) is $2.07B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
RMD
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$2.07B
YoY change
+24.8%
5Y CAGR
+14.1%
Peak year (2025)
$1.91B
Cumulative EBITDA
$14.20B
EBITDA history chart for ResMed (RMD) from 1993 to 2025
EBITDA history table for ResMed (RMD) from 1993 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $1.91B | +24.8% | ||
| 2024 | $1.53B | +12.9% | ||
| 2023 | $1.36B | +15.5% | ||
| 2022 | $1.18B | +6.6% | ||
| 2021 | $1.10B | +11.5% | ||
| 2020 | $990.43M | +40.3% | ||
| 2019 | $705.80M | +3.8% | ||
| 2018 | $680.22M | +19.6% | ||
| 2017 | $568.89M | +8.8% | ||
| 2016 | $522.72M | +8.4% | ||
| 2015 | $482.29M | -0.5% | ||
| 2014 | $484.87M | +3.2% | ||
| 2013 | $469.79M | +11.2% | ||
| 2012 | $422.59M | +12.9% | ||
| 2011 | $374.32M | +16.2% | ||
| 2010 | $322.15M | +69.3% | ||
| 2009 | $190.31M | -7.1% | ||
| 2008 | $204.83M | +127.2% | ||
| 2007 | $90.16M | -48.2% | ||
| 2006 | $174.04M | +27.1% | ||
| 2005 | $136.90M | +60.4% | ||
| 2004 | $85.36M | +6.9% | ||
| 2003 | $79.82M | -295.5% | ||
| 2002 | -$40.84M | -178.3% | ||
| 2001 | $52.16M | +32.4% | ||
| 2000 | $39.39M | +31.7% | ||
| 1999 | $29.90M | +42.4% | ||
| 1998 | $21.00M | +92.7% | ||
| 1997 | $10.90M | +122.4% | ||
| 1996 | $4.90M | +44.1% | ||
| 1995 | $3.40M | +112.5% | ||
| 1994 | $1.60M | +77.8% | ||
| 1993 | $900,000 | — |
EBITDA values are taken from ResMed's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
ResMed (RMD) most recent annual EBITDA stands at $1.91B (2025) – grew 24.8% year-over-year.
Over 2020–2025 (5 years), ResMed EBITDA expanded at a +14.1% compound annual rate, sustaining 10 straight years of year-over-year growth.
$1.91B stands as the all-time-high annual EBITDA, posted in 2025, against a low of -$40.84M during 2002.
Among 8 Healthcare peers, ResMed (RMD) ranks 9th; the peer median for EBITDA is $24.21B.
ResMed EBITDA by Year
ResMed EBITDA 2025: $1.91B
ResMed EBITDA in 2025 was $1.91B, grew 24.8% from 2024. This figure represents the highest annual value in the available history.
ResMed EBITDA 2024: $1.53B
ResMed EBITDA in 2024 was $1.53B, grew 12.9% from 2023.
ResMed EBITDA 2023: $1.36B
ResMed EBITDA in 2023 was $1.36B, grew 15.5% from 2022.
ResMed EBITDA 2022: $1.18B
ResMed EBITDA in 2022 was $1.18B, grew 6.6% from 2021.
ResMed EBITDA 2021: $1.10B
ResMed EBITDA in 2021 was $1.10B.
See more financial history for ResMed (RMD).
Sector peers — EBITDA
Companies in the same sector as ResMed, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is ResMed's EBITDA?
- Latest reported EBITDA for ResMed (RMD) is $2.07B (period ending December 31, 2025).
How has ResMed EBITDA changed year-over-year?
- ResMed (RMD) EBITDA changed +24.8% year-over-year on the latest annual filing.
What is the long-term growth rate of ResMed EBITDA?
- ResMed (RMD) EBITDA compound annual growth rate is +14.1% over the most recent 5 years available.
When did ResMed EBITDA hit its highest annual value?
- ResMed EBITDA reached its highest annual value of $1.91B in 2025.
What was ResMed EBITDA in 2024?
- ResMed (RMD) EBITDA in 2024 was $1.53B.
What was ResMed EBITDA in 2025?
- ResMed (RMD) EBITDA in 2025 was $1.91B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
RMD Overview
Company profile, financial tools, and key metrics
RMD Revenue Counter
Earns $171.17 every second. See per minute, hour, and day.
RMD Earnings Counter
Earns $47.12 per second net profit. See per minute, hour, and day.
RMD Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
RMD What If Invested
What if you had invested $1,000? See historical returns from any date.
RMD How It Makes Money
Discover visual breakdown of $5.40B in revenue — where it comes from and where it goes.
RMD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
RMD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
RMD Daily Price Character
Balanced · 50.4% historical win rate (green days). Streaks & record days.
RMD Buybacks
1.42% TTM buyback yield. Shareholder yield & SBC comparison.
RMD Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
RMD Dividend Profile
Yield: 1.10%. Safety: 6/8. See full history.
RMD Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
RMD Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.